Namitecan: A hydrophilic camptothecin with a promising preclinical profile

Current Medicinal Chemistry

Volumn 19, Issue 21, 2012, Pages 3488-3501

  Beretta, G L ^a   Zuco, V ^a   De Cesare, M ^a   Perego, P ^a   Zaffaroni, N ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

7 oxyiminomethyl derivatives; Antitumor therapy; Camptothecins; Cellular pharmacology; Clinical studies; Drug resistance; Gimatecan; Namitecan; Topoisomerase I; Tumor cells

Indexed keywords

7 (2 AMINOETHOXY)IMINOMETHYL CAMPTOTHECIN; BELOTECAN; CAMPTOTHECIN DERIVATIVE; COSITECAN; DB 67; DX 8951 F; EXATECAN; GIMATECAN; IRINOTECAN; LURTOTECAN; NAMITECAN; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; NONHUMAN; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

EID: 84863768731     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712801323252     Document Type: Article

References (113)

1. Stewart, L.; Redinbo, M.R.; Qiu, X.; Hol, W.G.; Champoux, J.J. A model for the mechanism of human topoisomerase I. Science, 1998, 279(5356), 1534-1541.
2. Pommier, Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem. Rev., 2009, 109(7), 2894-2902.
3. Pommier, Y.; Cherfils, J. Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. Trends Pharmacol. Sci., 2005, 6(3), 138-145.
4. Bjornsti, M.A.; Benedetti, P.: Viglianti, G.A.; Wang, J.C. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res., 1989, 49(22), 6318-6323.
5. Pommier, Y.; Leo, E.; Zhang, H.; Marchand, C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol., 2010; 17(5), 421-433.
6. Takimoto, C.H.; Wright, J.; Arbuck, S.G. Clinical applications of the camptothecins. Biochim Biophys Acta, 1998, 1400(1-3), 107-119.
7. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer, 2006, 6(10), 789-802.
8. Burke, T.G.; Mi, Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem., 1994, 37(1), 40-46.
9. Beretta, G.L.; Zunino, F. Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity. Biochem. Pharmacol., 2007, 74(10), 1437-1444.
10. Zunino, F.; Dallavalle, S.; Laccabue, D.; Beretta, G.; Merlini, L.; Pratesi, G. Current status and perspectives in the development of camptothecins. Curr Pharm Des., 2002, 8(27), 2505-2520.
11. Duffaud, F.; Borner, M.; Chollet, P.; Vermorken, J.B.; Bloch, J.; Degardin, M.; Rolland, F.; Dittrich, C.; Baron, B.; Lacombe, D.; Fumoleau, P. EORTC-New Drug Development Group/New Drug Development Program. Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study. Eur J Cancer, 2004, 40(18), 2748-2752.
12. Gelmon, K.; Hirte, H.; Fisher, B.; Walsh, W.; Ptaszynski, M.; Hamilton, M.; Onetto, N.; Eisenhauer, E. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Invest New Drugs, 2004, 22(3), 263-275.
13. Seiden, M.V.; Muggia, F.; Astrow, A.; Matulonis, U.; Campos, S.; Roche, M.; Sivret, J.; Rusk, J.; Barrett, E. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol., 2004, 93(1), 229-232.
14. Giles, F.J.; Tallman, M.S.; Garcia-Manero, G.; Cortes, J.E.; Thomas, D.A.; Wierda, W.G.; Verstovsek, S.; Hamilton, M.; Barrett, E.; Albitar, M.; Kantarjian, H.M. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer, 2004, 100(7), 1449-1458.
15. MacKenzie, M.J.; Hirte, H.W.; Siu, L.L.; Gelmon, K.; Ptaszynski, M.; Fisher, B.; Eisenhauer, E. A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. Ann Oncol., 2004, 15(4), 665-670.
16. Reichardt, P.; Nielsen, O.S.; Bauer, S.; Hartmann, J.T.; Schöffski, P.; Christensen, T.B.; Pink, D.; Daugaard, S.; Marreaud, S.; Van Glabbeke, M.; Blay, J.Y. Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer, 2007, 43(6), 1017-1022.
17. Abou-Alfa, G.K.; Letourneau, R.; Harker, G.; Modiano, M.; Hurwitz, H.; Tchekmedyian, N.S.; Feit, K.; Ackerman, J.; De Jager, R.L.; Eckhardt, S.G.; O'Reilly, E.M. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol., 2006, 24(27), 4441-4447.
18. Ajani, J.A.; Takimoto, C.; Becerra, C.R.; Silva, A.; Baez, L.; Cohn, A.; Major, P.; Kamida, M.; Feit, K.; De Jager, R. A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Invest New Drugs, 2005, 23(5), 479-484.
19. Abou-Alfa, G.K.; Rowinsky, E.K.; Patt, Y.Z.; Schwartz, G.K.; Kelsen, D.P.; Sharma, S.; Siegel, E.; Becerra, C.R.; Eckhardt, S.G.; Feit, K.; De Jager, R.; O'Reilly, E.M. A phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers. Am J Clin Oncol., 2005, 28(4), 334-339.
20. Hong, J.; Jung, M.; Kim, Y.J.; Sym, S.J.; Kyung, S.Y.; Park, J.; Lee, S.P.; Park, J.W.; Cho, E.K.; Jeong, S.H.; Shin, D.B.; Lee, J.H. Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer. Cancer Chemother Pharmacol., 2011, http://www.springerlink.com/content/dl23v261505142t4/fulltext.pdf (Accessed Decembrer 29, 2011).
21. Choi, C.H.; Lee, Y.Y.; Song, T.J.; Park, H.S.; Kim, M.K.; Kim, T.J.; Lee, J.W.; Lee, J.H.; Bae, D.S.; Kim, B.G. Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer. Cancer, 2011, 117(10), 2104-2111.
22. Wu, H.; Ramanathan, R.K.; Zamboni, B.A.; Strychor, S.; Ramalingam, S.; Edwards, R.P.; Friedland, D.M.; Stoller, R.G.; Belani, C.P.; Maruca, L.J.; Bang, Y.J.; Zamboni, W.C. Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. J Clin Pharmacol., 2011, http://jcp.sagepub.com/content/early/2011/01/13/0091270010394851.full.pdf (Accessed December 29, 2011).
23. Rhee, C.K.; Lee, S.H.; Kim, J.S.; Kim, S.J.; Kim, S.C.; Kim, Y.K.; Kang, H.H.; Yoon, H.K.; Song, J.S.; Moon, H.S.; Kim, J.W.; Kim, C.H.; Shim, B.Y.; Kim, H.K.; Sun, D.S.; Kim, K.H. A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer. Lung Cancer, 2011, 72(1), 64-67.
24. Zamboni, W.C.; Maruca, L.J.; Strychor, S.; Zamboni, B.A.; Ramalingam, S.; Edwards, R.P.; Kim, J.; Bang, Y.; Lee, H.; Friedland, D.M.; Stoller, R.G.; Belani, C.P.; Ramanathan, R.K. Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors. J Liposome Res., 2011, 21(2), 158-165.
25. Jeong, J.; Cho, B.C.; Sohn, J.H.; Choi, H.J.; Kim, S.H.; Lee, Y.J.; Jung, M.K.; Shin, S.J.; Park, M.S.; Kim, S.K.; Chang, J.; Kim, J.H. Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial. Lung Cancer., 2010, 70(1), 77-81.
26. Lee, D.H.; Kim, S.W.; Suh, C.; Lee, J.S.; Ahn, J.S.; Ahn, M.J.; Park, K.; Na, I.I.; Lee, J.C.; Ryoo, B.Y.; Yang, S.H. Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer. Cancer, 2010, 116(1), 132-136.
27. Van Hattum, A.H.; Pinedo, H.M.; Schlüper, H.M.; Hausheer, F.H.; Boven, E. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer., 2000, 88(2), 260-266.
28. Bom, D.; Curran, D.P.; Kruszewski, S.; Zimmer, S.G.; Thompson Strode, J.; Kohlhagen, G.; Du, W.; Chavan, A.J.; Fraley, K.A.; Bingcang, A.L.; Latus, L.J.; Pommier, Y.; Burke, T.G.; The novel silatecan 7-tert-butyldimethylsilyl-10- hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem., 2000, 43(21), 3970-3980.
29. Daud, A.; Valkov, N.; Centeno, B.; Derderian, J.; Sullivan, P.; Munster, P.; Urbas, P.; Deconti, R.C.; Berghorn, E.; Liu, Z.; Hausheer, F.; Sullivan, D. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin Cancer Res., 2005, 11(8), 3009-3016.
30. Arnold, S.M.; Rinehart, J.J.; Tsakalozou, E.; Eckardt, J.R.; Fields, S.Z.; Shelton, B.J.; DeSimone, P.A.; Kee, B.K.; Moscow, J.A.; Leggas, M. A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies. Clin Cancer Res., 2010, 16(2), 673-680.
31. Pratesi, G.; Beretta, G.L.; Zunino, F. Gimatecan, a novel camptothecin with a promising preclinical profile. Anticancer Drugs., 2004, 15(6), 545-552.
32. Zucchetti, M.; Meco, D.; Di Francesco, A.M.; Servidei, T.; Patriarca, V.; Cusano, G.; D'Incalci, M.; Forestieri, D.; Pisano, C.; Riccardi, R. Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts. Cancer Chemother Pharmacol., 2010, 66(4), 635-641.
33. Di Francesco, A.M.; Riccardi, A.; Barone, G.; Rutella, S.; Meco, D.; Frapolli, R.; Zucchetti, M.; D'Incalci, M.; Pisano, C.; Carminati, P.; Riccardi, R. The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan. Biochem Pharmacol., 2005, 70(8), 1125-1136.
34. Biroccio, A.; Porru, M.; Rizzo, A.; Salvati, E.; D'Angelo, C.; Orlandi, A.; Passeri, D.; Franceschin, M.; Stevens, M.F.; Gilson, E.; Beretta, G.; Zupi, G.; Pisano, C.; Zunino, F.; Leonetti, C. DNA damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents. Clin Cancer Res., 2011, 17(8), 2227-2236.
35. Fabbri, F.; Brigliadori, G.; Carloni, S.; Ulivi, P.; Tesei, A.; Silvestrini, R.; Amadori, D.; Zoli, W. Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression. Prostate, 2010, 70(2), 219-227.
36. Marchetti, S.; Oostendorp, R.L.; Pluim, D.; van Eijndhoven, M.; van Tellingen, O.; Schinkel, A.H.; Versace, R.; Beijnen, J.H.; Mazzanti, R.; Schellens, J.H. In vitro transport of gimatecan (7-t-butoxyiminometh- ylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2. Mol Cancer Ther., 2007, 6(12 Pt 1), 3307-3313.
37. Gounder, M.K.; Nazar, A.S.; Saleem, A.; Pungaliya, P.; Kulkarni, D.; Versace, R.; Rubin, E.H. Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan. Invest New Drugs., 2008, 26(3), 205-213.
38. Oostendorp, R.L.; van de Steeg, E.; van der Kruijssen, C.M.; Beijnen, J.H.; Kenworthy, K.E.; Schinkel, A.H.; Schellens, J.H. Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos., 2009, 37(4), 917-923.
39. Perego, P.; Cossa, G.; Tinelli, S.; Corna, E.; Carenini, N.; Gatti, L.; De Cesare, M.; Ciusani, E.; Zunino, F.; Luison, E.; Canevari, S.; Zaffaroni, N.; Beretta, G.L. Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition. Biochem Pharmacol., 2012, 83(1), 27-36.
40. El-Khamisy, S.F.; Saifi, G.M.; Weinfeld, M.; Johansson, F.; Helleday, T.; Lupski, J.R.; Caldecott, K.W. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature, 2005, 434(7029), 108-113.
41. Gajewski, S.; Comeaux, E.Q.; Jafari, N.; Bharatham, N.; Bashford, D.; White, S.W.; van Waardenburg, R.C. Analysis of the active-site mechanism of tyrosyl-DNA phosphodiesterase I: a member of the phospholipase D superfamily. J Mol Biol., 2012, 415(4), 741-758.
42. Huang, S.N.; Pommier, Y.; Marchand, C. Tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibitors. Expert Opin Ther Pat., 2011, 21(9), 1285-1292.
43. Beretta GL, Cossa G, Gatti L, Zunino F, Perego P. Tyrosyl-DNA phosphodiesterase 1 targeting for modulation of camptothec in-based treatment. Curr Med Chem., 2010, 17(15), 1500-1508.
44. Staker, B.L.; Hjerrild, K.; Feese, M.D.; Behnke, CA.; Burgin, A.B. Jr.; Stewart, L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl. Acad. Sci. U. S. A., 2002, 99(24), 15387-15392.
45. Sugimori, M.; Ejima, A.; Ohsuki, S.; Uoto, K.; Mitsui, I; Kawato, Y.; Hirota, Y.; Sato, K.; Terasawa, H. Synthesis and antitumor activity of ring A-and F-modified hexacyclic camptothecin analogues. J Med Chem., 1998, 41(13), 2308-2318.
46. Luzzio, M.J.; Besterman, J.M.; Emerson, D.L.; Evans, M.G.; Lackey, K.; Leitner, PL.; McIntyre, G.; Morton, B.; Myers, PL.; Peel, M.; Sisco, J.M.; Sternbach, D.D.;Tong, W.; Truesdale, A.; Uehling, D.E.;Vuong, A.; Yates, J. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J Med Chem., 1995, 38(3), 395-401.
47. Vladu, B.; Woynarowski, J.M.; Manikumar, G.; Wani, M.C.; Wall, M.E.; Von Hoff, D.D.; Wadkins, RM. 7-and 10-substituted camptothecins: dependence of topoisomerase I-DNA cleavable complex formation and stability on the 7-and 10-substituents. Mol Pharmacol, 2000, 57(2), 243-251.
48. Staker, B.L.; Feese, M.D.; Cushman, M.; Pommier, Y; Zembower, D.; Stewart, L.; Burgin, A.B. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J. Med. Chem., 2005, 48(7), 2336-2345.
49. Tanizawa, A.; Fujimori, A.; Fujimori, Y; Pommier, Y Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst., 1994, 86(11), 836-842.
50. Bom, D.; Curran, D.P; Zhang, J.; Zimmer, S.G.; Bevins, R.; Kruszewski, S.; Howe, J.N.; Bingcang, A.; Latus, L.J.; Burke, T.G. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. J Control Release., 2001, 74(1-3), 325-333.
51. Pollack, IF; Erff, M.; Bom, D.; Burke, T.G.; Strode, J.T.; Curran, D.P. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Cancer Res., 1999, 59(19), 4898-4905.
52. Jaxel, C; Kohn, K.W.; Wani, M.C.; Wall, M.E.; Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res., 1989, 49(6), 1465-1469.
53. Dallavalle, S.; Delsoldato, T.; Ferrari, A.; Merlini, L.; Penco, S.; Carenini, N; Perego, P.; De Cesare, M.; Pratesi, G.; Zunino, F. Novel 7-substituted camptothecins with potent antitumor activity. J Med Chem., 2000, 43(21), 3963-3969.
54. Dallavalle, S.; Ferrari, A.; Merlini, L.; Penco, S.; Carenini, N; De Cesare, M.; Perego, P.; Pratesi, G.; Zunino, F. Novel cytotoxic 7-iminomethyl and 7-aminomethyl derivatives of camptothecin. Bioorg Med Chem Lett., 2001, 11(3), 291-294.
55. Dallavalle, S.; Merlini, L.; Morini, G.; Musso, L.; Penco, S.; Beretta, G.L.; Tinelli, S.; Zunino, F Synthesis and cytotoxic activity of substituted 7-aryliminomethyl derivatives of camptothecin. Eur J Med Chem., 2004, 39(6), 507-513.
56. Dallavalle, S.; Ferrari, A.; Biasotti, B.; Merlini, L.; Penco, S.; Gallo, G.; Marzi, M.; Tinti, M.O.; Martinelli, R.; Pisano, C; Carminati, P.; Carenini, N.; Beretta, G.; Perego, P.; De Cesare, M.; Pratesi, G.; Zunino, F. Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. J Med Chem., 2001, 44(20), 3264-3274.
57. Dallavalle, S.; Rocchetta, D.G.; Musso, L.; Merlini, L.; Morini, G.; Penco, S.; Tinelli, S.; Beretta, G.L.; Zunino, F Synthesis and cytotoxic activity of new 9-substituted camptothecins. Bioorg Med Chem Lett., 2008, 18(9), 2781-2787.
58. Dallavalle, S.; Giannini, G.; Alloatti, D.; Casati, A.; Marastoni, E.; Musso, L.; Merlini, L.; Morini, G.; Penco, S.; Pisano, C; Tinelli, S.; De Cesare, M.; Beretta, G.L.; Zunino, F Synthesis and cytotoxic activity of polyamine analogues of camptothecin. J Med Chem., 2006, 49(17), 5177-5186.
59. 3 integrin ligands: An approach to tumor-targeted therapy. Bioconjug Chem., 2010, 21(11), 1956-1967.
60. Dal Pozzo, A.; Ni, M.H.; Esposito, E.; Dallavalle, S.; Musso, L.; Bargiotti, A.; Pisano, C; Vesci, L.; Bucci, F.; Castorina, M.; Foderà, R.; Giannini, G.; Aulicino, C; Penco, S. Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation. Bioorg Med Chem., 2010, 18(1), 64-72.
61. Vekhoff, P.; Halby, L.; Oussedik, K.; Dallavalle, S.; Merlini, L.; Mahieu, C; Lansiaux, A.; Bailly, C; Boutorine, A.; Pisano, C; Giannini, G.; Alloatti, D.; Arimondo, PB. Optimized synthesis and enhanced efficacy of novel triplex-forming camptothecin derivatives based on gimatecan. Bioconjug Chem., 2009, 20(4), 666-672.
62. Oussedik, K.; François, J.C.; Halby, L.; Senamaud-Beaufort, C; Toutirais, G.; Dallavalle, S.; Pommier, Y; Pisano, C; Arimondo, PB. Sequence-specific targeting of IGF-I and IGF-IR genes by camptothecins. FASEB J., 2010, 24(7), 2235-2244.
63. Seiler, N; Dezeure, F; Moulinoux, J.P Polyamines transport in mammalian cells. An update. Int. J. Biochem. Cell Biol, 1996, 28(8), 843-861.
64. Volkow, N.; Goldman, S.S.; Flamm, E.S.; Cravioto, H.; Wolf, A.P.; Brodie, J. D. Labeled putrescine as a probe in brain tumors. Science, 1983, 221(4611), 673-675.
65. Edwards, M.L.; Snyder, R.D.; Stemerick, D.M. Synthesis and DNA-binding properties of polyamine analogues. J. Med. Chem., 1991, 34(8), 2414-2420.
66. Shao, R.G.; Cao, C.X.; Shimizu, T.; O'Connor, P.M.; Kohn, K.W., Pommier, Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res., 1997, 57(18), 4029-4035.
67. Strumberg, D.; Pilon, A.A.; Smith, M.; Hickey, R.; Malkas, L.; Pommier, Y. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff. Mol. Cell. Biol, 2000, 20(11), 3977-3987.
68. Lee, S.; Lee, H.S.; Baek, M.; Lee, D.Y; Bang, Y.J.; Cho, H.N.; Lee, Y.S.; Ha, J.H.; Kim, H. Y; Jeoung, D.I. MAPK signaling is involved in camptothecin-induced cell death. Mol Cells, 2002, 14(3), 348-354.
69. Kinders, R.J.; Hollingshead, M.; Lawrence, S.; Ji, J.; Tabb, B.; Bonner, W.M.; Pommier, Y; Rubinstein, L.; Evrard, Y A.; Parchment, R.E.; Tomaszewski, J.; Doroshow, J.H. Development of a validated immunofluorescence assay for yH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity. Clin. Cancer Res., 2010, 16(22), 5447-5457.
70. Huang, X.; Traganos, F.; Darzynkiewicz, Z. DNA damage induced by DNA topoisomerase I-and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis. Cell Cycle, 2003, 2(6), 614-619.
71. Furuta, T.; Takemura, H.; Liao, Z.Y; Aune, G.J.; Redon, C; Sedelnikova, O.A.; Pilch, D.R.; Rogakou, E.P; Celeste, A.; Chen, H.T.; Nussenzweig, A.; Aladjem, M.I.; Bonner, W.M.; Pommier, Y Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J. Biol. Chem., 2003, 278(22), 20303-20312.
72. Han, B.; Stockwin, L.H.; Hancock, C; Yu, S.X.; Hollingshead, M.G.; Newton, D.L. Proteomic analysis of nuclei isolated from cancer cell lines treated with indenoisoquinoline NSC 724998, a novel topoisomerase I inhibitor. J. Proteome Res., 2010, 9(8), 4016-4027.
73. Zuco, V.; Supino, R.; Favini, E.; Tortoreto, M.; Cincinelli, R.; Croce, A.C.; Bucci, F.; Pisano, C; Zunino, F Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma. Biochem Pharmacol, 2010, 79(4), 535-541.
74. De Cesare, M.; Beretta, G.L.; Tinelli, S.; Benedetti, V.; Pratesi, G.; Penco, S.; Dallavalle, S.; Merlini, L.; Pisano, C.; Carminati, P.; Zunino, F. Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series. Biochem Pharmacol, 2007, 73(5), 656-664.
75. Pisano, C; Zuco, V.; De Cesare, M.; Benedetti, V.; Vesci, L.; Foderà, R.; Bucci, F.; Aulicino, C; Penco, S.; Carminati, P.; Zunino F Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968. Eur J Cancer., 2008, 44(9), 1332-1340.
76. Zhang, H.; Barceló, J.M.; Lee, B.; Kohlhagen, G.; Zimonjic, D.B.; Popescu, N.C.; Pommier, Y Human mitochondrial topoisomerase I. Proc Natl Acad Sci U S A., 2001, 98(19), 10608-10613.
77. de la Loza, M.C.; Wellinger, R.E. A novel approach for organelle-specific DNA damage targeting reveals different susceptibility of mitochondrial DNA to the anticancer drugs camptothecin and topotecan. Nucleic Acids Res., 2009, 37(4) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651790/pdf/gkn1087.pdf (Accessed December 2, 2011).
78. Pisano, C; De Cesare, M.; Beretta, G.L.; Zuco, V.; Pratesi, G.; Penco, S.; Vesci, L.; Foderà, R.; Ferrara, F.F.; Guglielmi, M.B.; Carminati, P.; Dallavalle, S.; Morini, G.; Merlini, L.; Orlandi, A.; Zunino, F Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968. Mol Cancer Ther., 2008, 7(7), 2051-2059.
79. Jensen, A.D.; Svejstrup, J.Q. Purification and characterization of human topoisomerase I mutants. Eur J Biochem., 1996, 236(2), 389-394.
80. Chrencik, J.E.; Staker, B.L.; Burgin, A.B.; Pourquier, P.; Pommier, Y; Stewart, L.; Redinbo, M.R. Mechanisms of camptothecin resistance by human topoisomerase I mutations. J Mol Biol, 2004, 339(4), 773-784.
81. Zuco, V.; Supino, R.; De Cesare, M.; Carenini, N; Perego, P.; Gatti, L.; Pratesi, G.; Pisano, C; Martinelli, R.; Bucci, F.; Zanier, R.; Carminati, P.; Zunino, F. Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models. Biochem Pharmacol, 2003, 65(8), 1281-1294.
82. Pratesi, G.; De Cesare, M.; Carenini, N; Perego, P.; Righetti, S.C.; Cucco, C; Merlini, L.; Pisano, C; Penco, S.; Carminati, P.; Vesci, L.; Zunino, F. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Clin Cancer Res., 2002, 8(12), 3904-3909.
83. Zuco, V; Benedetti, V; Zunino, F ATM-and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968. Cancer Lett., 2010, 292(2), 186-196.
84. Miller, A.A.; Herndon, J.E.; Gu, L.; Green, M.R. Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). Lung Cancer, 2005, 48(3), 399-407.
85. Daud, A.I.; Dawson, J.; DeConti, R.C.; Bicaku, E.; Marchion, D.; Bastien, S.; Hausheer, F.A.; Lush, R.; Neuger, A.; Sullivan, D.M.; Munster, P.N. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res., 2009, 15(7), 2479-2487.
86. Munster, P.N.; Daud, A.I. Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. Expert Opin Investig Drugs, 2011, 20(11), 1565-1574.
87. Hwang, J.H.; Lim, M.C.; Seo, S.S.; Park, S.Y.; Kang, S. Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix. Jpn J Clin Oncol., 2011, 41(5), 624-629.
88. Lee, H.P.; Seo, S.S.; Ryu, S.Y.; Kim, J.H.; Bang, Y.J.; Park, S.Y.; Nam, J.H.; Kang, S.B.; Lee, K.H.; Song, Y.S. Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or-resistant ovarian cancer. Gynecol Oncol., 2008, 109(3), 359-363.
89. Lee, D.H.; Kim, S.W.; Suh, C.; Lee, J.S.; Lee, J.H.; Lee, S.J.; Ryoo, B.Y.; Park, K.; Kim, J.S.; Heo, D.S.; Kim, N.K. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Ann Oncol., 2008, 19(1), 123-127.
90. Giles, F.J.; Cortes, J.E.; Thomas, D.A.; Garcia-Manero, G.; Faderl, S.; Jeha, S.; De Jager, R.L. Kantarjian HM. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res., 2002, 8(7), 2134-2141.
91. Rowinsky, E.K.; Johnson, T.R.; Geyer, C.E.; Hammond, L.A.; Eckhardt, S.G.; Drengler, R.; Smetzer, L.; Coyle, J.; Rizzo, J.; Schwartz, G.; Tolcher, A.; Von Hoff, D.D.; De Jager, R.L. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol., 2000, 18(17), 3151-3163.
92. De Jager, R.; Cheverton, P.; Tamanoi, K.; Coyle, J.; Ducharme, M.; Sakamoto, N.; Satomi, M.; Suzuki, M. DX-8931f Investigators. DX-8951f: summary of phase I clinical trials. Ann N Y Acad Sci., 2000, 922, 260-273.
93. Royce, M.E.; Hoff, P.M.; Dumas, P.; Lassere, Y.; Lee, J.J.; Coyle, J.; Ducharme, M.P.; De Jager, R.; Pazdur, R. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. J Clin Oncol., 2001, 19(5), 1493-1500.
94. Garrison, M.A.; Hammond, L.A.; Geyer, C.E.; Schwartz, G.; Tolcher, A.W.; Smetzer, L.; Figueroa, J.A.; Ducharme, M.; Coyle, J.; Takimoto, C.H.; De Jager, R.L.; Rowinsky, E.K. A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies. Clin Cancer Res., 2003, 9(7), 2527-2537.
95. Kuppens, I.E.; Beijnen, J.; Schellens, J.H. Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration. Clin Colorectal Cancer, 2004, 4(3), 163-180.
96. Esteva, F.J.; Rivera, E.; Cristofanilli, M.; Valero, V.; Royce, M.; Duggal, A.; Colucci, P.; DeJager, R.; Hortobagyi, G.N. A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer, 2003, 98(5), 900-907.
97. Braybrooke, J.P.; Ranson, M.; Manegold, C.; Mattson, K.; Thatcher, N.; Cheverton, P.; Sekiguchi, M.; Suzuki, M.; Oyama, R.; Talbot, D.C. Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer. Lung Cancer, 2003, 41(2), 215-219.
98. Clamp, A.; Adams, M.; Atkinson, R.; Boven, E.; Calvert, A.H.; Cervantes, A.; Ganesan, T.; Lotz, J.; Vasey, P.; Cheverton, P.; Jayson, G.C. A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum-and taxane-resistant/refractory ovarian cancer. Gynecol Oncol., 2004, 95(1), 114-119.
99. Verschraegen, C.F.; Kudelka, A.P.; Hu, W.; Vincent, M.; Kavanagh, J.J.; Loyer, E.; Bastien, L.; Duggal, A.; De Jager, R. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Cancer Chemother Pharmacol., 2004, 53(1), 1-7.
100. Zhu, A.X.; Ready, N.; Clark, J.W.; Safran, H.; Amato, A.; Salem, N.; Pace, S.; He, X.; Zvereva, N.; Lynch, T.J.; Ryan, D.P.; Supko, J.G. Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. Clin Cancer Res., 2009, 15(1), 374-381.
101. Sessa, C.; Cresta, S., Cerny, T.; Baselga, J.; Rota Caremoli, E.; Malossi, A.; Hess, D.; Trigo, J.; Zucchetti, M.; D'Incalci, M.; Zaniboni, A.; Capri, G.; Gatti, B.; Carminati, P.; Zanna, C.; Marsoni, S.; Gianni, L. Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. Ann Oncol., 2007, 18(3), 561-568.
102. Fasolo, A.; Del Conte, G.; Calderone, R.G.; Gallerani, E.; Hagner, N.; Barbieri, P.; Luraghi, L.; Pace, S.; Capocasa, F.; Coceani, N.; Maccioni, E.; Hess, D.; Sessa, C.; Gianni, L. Phase I clinical trial of namitecan (ST1968): Results with D1-3 q3wks schedule. Proceedings of the ASCO Annual Meeting 2011, Chicago, Illinois June 3-7. J Clin Oncol Vol 29, No 15 suppl (May 20 Supplement), 2011: e13570
103. Hess, D.; Boehm, S.; Delmonte, A.; Gallerani, E.; Barbieri, P., Pace, S.; Carminati, P., Marsoni, S.; Coceani, N.; Sessa, C. Clinical development of namitecan (ST1968), a novel camptothecin derivative with high antitumor activity: Phase I clinical data. Proceedings of the ASCO Annual Meeting 2009 May30-june2 J Clin Oncol Vol 27, No 15S (May 20 Supplement), 2009: 2570
104. Frapolli, R.; Zucchetti, M.; Sessa, C.; Marsoni, S.; Viganò, L.; Locatelli, A.; Rulli, E.; Compagnoni, A.; Bello, E.; Pisano, C.; Carminati, P.; D'Incalci, M. Clinical pharmacokinetics of the new oral camptothecin gimatecan: the interpatient variability is related to alpha1-acid glycoprotein plasma levels. Eur J Cancer., 2010, 46(3), 505-516.
105. Pace, S.; Capocasa, F.; Tallarico, C.; Frapolli, R.; Zucchetti, M.; Longo, A. Determination of total and lactone form of a new camptothecin derivative gimatecan (ST1481) and its metabolite ST1698 in human plasma by highperformance liquid chromatography with fluorimetric detection. J Pharm Biomed Anal., 2009, 50(3), 507-514.
106. Pecorelli, S.; Ray-Coquard, I.; Tredan, O.; Colombo, N.; Parma, G.; Tisi, G.; Katsaròs, D.; Lhommé, C.; Lissoni, A.A.; Vermorken, J.B.; du Bois, A.; Poveda, A.; Frigerio, L.; Barbieri, P.; Carminati, P.; Brienza, S.; Guastalla, J.P. Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Ann Oncol., 2010, 21(4), 759-765.
107. Beretta, G.L.; Zuco, V.; Perego, P.; Zaffaroni, N. Targeting DNA Topoisomerase I with Non-camptothecin Poisons. Curr Med Chem., 2012, 19(8), 1238-1257.
108. Rapisarda, A.; Uranchimeg, B.; Sordet, O.; Pommier, Y.; Shoemaker, R.H.; Melillo, G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res., 2004, 64(4), 1475-1482.
109. Bertozzi, D.; Iurlaro, R.; Sordet, O.; Marinello, J.; Zaffaroni, N.; Capranico, G. Characterization of novel antisense HIF-1a transcripts in human cancers. Cell Cycle, 2011, 10(18), 3189-197.
110. Cassinelli, G.; Zuco, V.; Petrangolini, G.; De Cesare, M.; Tortoreto, M.; Lanzi, C.; Cominetti, D.; Zaffaroni, N.; Orlandi, A.; Passeri, D.; Meco, D.; Di Francesco, A.M.; Riccardi, R.; Bucci, F.; Pisano, C.; Zunino, F The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects. Biochem Pharmacol., 2012, in press.
111. Nozoe, T.; Yasuda, M.; Honda, M.; Imutsuka, S.; Korenaga, D. Experimental evidence for the efficacy of combined therapy of CPT-11 and hyperthermia for squamous cell carcinoma of the esophagus. Hepatogastroenterology, 2007, 54(80), 2272-2275.
112. Long, H.J. Management of metastatic cervical cancer: review of the literature. J Clin Oncol, 2007, 25(20), 2955-2974.
113. Murphy, B.A. Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck. Exp Opin Pharmacother., 2005, 6(1), 85-92.